Literature DB >> 9305619

Myeloblasts from Down syndrome children with acute myeloid leukemia have increased in vitro sensitivity to cytosine arabinoside and daunorubicin.

J W Taub, M L Stout, S A Buck, X Huang, R A Vega, D L Becton, Y Ravindranath.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9305619     DOI： 10.1038/sj.leu.2400747

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  5 in total

1.  Transcriptional regulation of the human cystathionine beta-synthase -1b basal promoter: synergistic transactivation by transcription factors NF-Y and Sp1/Sp3.

Authors:  Y Ge; M A Konrad; L H Matherly; J W Taub
Journal:  Biochem J       Date:  2001-07-01       Impact factor: 3.857

2.  Distinctive multidrug sensitivity and outcome of acute erythroblastic and megakaryoblastic leukemia in children with Down syndrome.

Authors:  S Yamada; T Hongo; S Okada; C Watanabe; Y Fujii; H Hori; M Yazaki; R Hanada; Y Horikoshi
Journal:  Int J Hematol       Date:  2001-12       Impact factor: 2.490

3.  Methotrexate-induced side effects are not due to differences in pharmacokinetics in children with Down syndrome and acute lymphoblastic leukemia.

Authors:  Trudy D Buitenkamp; Ron A A Mathôt; Valerie de Haas; Rob Pieters; C Michel Zwaan
Journal:  Haematologica       Date:  2010-04-23       Impact factor: 9.941

Review 4.  Clinical and biological aspects of myeloid leukemia in Down syndrome.

Authors:  Austin C Boucher; Kenneth J Caldwell; John D Crispino; Jamie E Flerlage
Journal:  Leukemia       Date:  2021-09-13       Impact factor: 12.883

Review 5.  Factors in improved survival from paediatric cancer.

Authors:  J W Taub
Journal:  Drugs       Date:  1998-11       Impact factor: 9.546
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.